company background image
NB11 logo

Vaxart DB:NB11 Stock Report

Last Price

€1.16

Market Cap

€202.1m

7D

13.6%

1Y

66.8%

Updated

25 Mar, 2024

Data

Company Financials +

NB11 Stock Overview

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform.

NB11 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Vaxart, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vaxart
Historical stock prices
Current Share PriceUS$1.16
52 Week HighUS$1.39
52 Week LowUS$0.50
Beta0.44
1 Month Change-4.83%
3 Month Change116.31%
1 Year Change66.81%
3 Year Change-76.38%
5 Year Changen/a
Change since IPO68.41%

Recent News & Updates

Recent updates

Shareholder Returns

NB11DE BiotechsDE Market
7D13.6%3.3%1.6%
1Y66.8%35.8%6.4%

Return vs Industry: NB11 exceeded the German Biotechs industry which returned 35.3% over the past year.

Return vs Market: NB11 exceeded the German Market which returned 6.4% over the past year.

Price Volatility

Is NB11's price volatile compared to industry and market?
NB11 volatility
NB11 Average Weekly Movement14.2%
Biotechs Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: NB11's share price has been volatile over the past 3 months.

Volatility Over Time: NB11's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a109Steven Lohttps://vaxart.com

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical dysplasia. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.

Vaxart, Inc. Fundamentals Summary

How do Vaxart's earnings and revenue compare to its market cap?
NB11 fundamental statistics
Market cap€202.11m
Earnings (TTM)-€76.08m
Revenue (TTM)€6.81m

29.0x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NB11 income statement (TTM)
RevenueUS$7.38m
Cost of RevenueUS$68.14m
Gross Profit-US$60.76m
Other ExpensesUS$21.70m
Earnings-US$82.46m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.47
Gross Margin-823.46%
Net Profit Margin-1,117.56%
Debt/Equity Ratio0%

How did NB11 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.